✦ LIBER ✦

Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab

✍ Scribed by Vera, R.; Gomez Dorronsoro, M.; Lopez-Ben, S.; Viudez, A.; Queralt, B.; Hernandez, I.; Ortiz-Duran, M. R.; Zazpe, C.; Soriano, J.; Amat, I.; Herrera Cabezón, J.; Diaz, E.; Codina-Barreras, A.; Hernandez-Yagüe, X.; Quera, A.; Figueras, J.

Book ID: 121590420
Publisher: Springer Milan
Year: 2013
Tongue: Spanish
Weight: 260 KB
Volume: 16
Category: Article
ISSN: 1699-048X
DOI: 10.1007/s12094-013-1142-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab Improves Pathological Respon

Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX

✍ Markus Klinger; Dietmar Tamandl; Sandra Eipeldauer; Stefan Hacker; Beata Herberg 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 231 KB

Complete pathological response of colore

Complete pathological response of colorectal liver metastases after chemotherapy and bevacizumab treatment: a case report

✍ F. Vitiello; V. Ricci; E. Martinelli; M. Orditura; F. DeVita; G. Galizia; F. Cia 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 107 KB

Pathologic response to bevacizumab-conta

Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival

✍ Gruenberger, T.; Arnold, D.; Rubbia-Brandt, L. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 558 KB

A retrospective analysis of periodontiti

A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients

✍ Ogawa, Kohei; Ueno, Takao; Kato, Ken; Nishitani, Hitoshi; Akiyoshi, Kohei; Iwasa 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 233 KB

Histopathologic evaluation of liver meta

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

✍ Loupakis, F; Schirripa, M; Caparello, C; Funel, N; Pollina, L; Vasile, E; Cremol 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 638 KB

Bevacizumab improves pathologic response

Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases

✍ Dario Ribero; Huamin Wang; Matteo Donadon; Daria Zorzi; Melanie B. Thomas; Cathy 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB

## Abstract ## BACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidine‐plus‐oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. ## METHODS. A total of 105 consecutive patients trea